PEG

PROTAC α-synuclein degrader 5 is a selective small-molecule degrader targeting α-synuclein aggregates. It features the probe molecule sery308 along with E3 ligase ligands, facilitating significant degradation activity. This compound is a valuable resource for research in neurological disorders.

PROTAC BRD4 Degrader-9 is a bifunctional compound that utilizes ligands for von Hippel-Lindau and BRD4 to facilitate targeted degradation. It can be conjugated with STEAP1 and CLL1 antibodies, enhancing its effectiveness in degrading BRD4 protein within prostate cancer cell lines.

ARD-2051 is a highly effective orally bioavailable degrader designed to target the androgen receptor (AR) for proteolysis. This compound demonstrates significant potency in degrading AR protein in prostate cancer cell lines such as LNCaP and VCaP, making it valuable for research into AR-related pathways.

INY-05-040 is a selective AKT degrader that targets all three AKT isoforms, effectively disrupting downstream signaling and inhibiting cell proliferation across various cancer cell lines.

PROTAC TTK Degrader-1 is a potent degrader targeting threonine tyrosine kinase (TTK), designed to induce TTK degradation in specific cell lines. It exhibits strong activity in cellular models and demonstrates efficacy in modulating protein levels for research purposes.

PRO-6E is an orally active PROTAC designed to target MET for degradation. It incorporates a Cereblon ligand, a linker, and a MET inhibitor moiety, facilitating selective degradation of MET in cellular models. The compound effectively modulates protein levels and induces cellular apoptosis and arrest, making it valuable for research into MET-related pathways.

HD-TAC7 is a potent PROTAC that targets HDAC1, HDAC2, and HDAC3 for degradation. Structurally, it integrates an HDAC-binding ligand and an E3 ligase recruiter, leading to selective modulation of HDAC activity. HD-TAC7 also influences NF-κB p65 levels in macrophages, making it useful for studying inflammatory pathways.

PROTAC BRD4 Degrader-19 is a molecule designed to induce degradation of the BRD4 protein through a PROTAC mechanism. It consists of ligands that bind BRD4 and an E3 ligase, facilitating targeted protein degradation, and is useful for studying BRD4-related pathways.

NUCC-0226272 is a potent PROTAC designed to induce degradation of EZH2, showing significant anti-proliferative properties. It is useful for investigating EZH2-related biological pathways.